The US Food and Drug Administration (FDA) has awarded breakthrough therapy designation to uniQure's AMT-130 for treating ...

Chorea is a characteristic type of involuntary movement in Huntington’s disease. This movement is often described as a smooth, writhing, squirmy, or twisting motion. It can affect any part of ...

"Pridopidine shows long-term sustained efficacy up to 2 years, and there's significant long-term benefit confirmed compared ...

Ingrezza (valbenazine) is a brand-name oral capsule prescribed for tardive dyskinesia and Huntington’s chorea. The cost of the drug with and without insurance can depend on several factors.

Vesicular monoamine transporter 2 (VMAT2) inhibitors are a type of medication used to manage a specific type of motor symptom in Huntington’s disease known as chorea. Chorea refers to the ...

Qure's AMT-130 receives FDA Breakthrough Therapy designation for Huntington's disease, adding to Fast Track, RMAT, and Orphan ...

These include helping infertile couples who have had no luck with other infertility treatments to have children or allowing a parent bearing a gene for a debilitating disease such as Huntington's ...

Breakthrough Therapy designation based on clinical evidence from Phase I/II trials showing meaningful slowing of disease progression ~~ ...

The fellows gain expertise in diagnosing and treating Parkinson’s disease, atypical Parkinsonian syndromes, tremor, dystonia, Huntington’s disease, chorea, ataxia, myoclonus, ballism, Tourette ...

Huntington's disease (HD) is a hereditary neurodegenerative disorder ... The movement disorder is characterized by involuntary movements known as chorea, and by the impairment of voluntary movements.

Huntington’s disease is a rare, inherited neurodegenerative disorder that leads to motor symptoms including chorea, behavioral abnormalities and cognitive decline resulting in progressive ...